Valneva SE (VALN) Other Accumulated Expenses (2023 - 2026)
Valneva SE (VALN) posted Other Accumulated Expenses of $6.3 million for Q1 2026, down 4.34% sequentially from $6.6 million in Q4 2025, and up 33.21% YoY from $4.8 million in Q1 2025.
Analysis
Valneva SE (VALN) Other Accumulated Expenses (2023 - 2026) Analysis & Trends
Valneva SE has reported Other Accumulated Expenses for 4 years, with the latest figure at $6.3 million in Q1 2026.
- Quarterly Other Accumulated Expenses rose 33.21% year-over-year to $6.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.3 million (up 33.21% YoY) and the FY2025 annual result came in at $6.6 million, up 18.76% from the prior year.
- Other Accumulated Expenses slipped to $6.3 million in Q1 2026 per VALN's latest filing, from $6.6 million in the prior quarter.
- Over five years, Other Accumulated Expenses peaked at $10.8 million in Q2 2025 and troughed at $636956.4 in Q4 2023.
- A 4-year average of $6.2 million and a median of $6.3 million in 2026 frame the typical range for Other Accumulated Expenses.
- The sharpest annual moves came in 2024 and 2025: Other Accumulated Expenses jumped 764.33% in 2024, then increased 20.29% in 2025.
- Over 4 years, Other Accumulated Expenses stood at $636956.4 in 2023, then soared by 764.33% to $5.5 million in 2024, then climbed by 20.29% to $6.6 million in 2025, then fell by 4.34% to $6.3 million in 2026.
- According to Business Quant data, Other Accumulated Expenses over the past three periods registered $6.3 million, $6.6 million, and $8.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Valneva SE | 578.54 Mn | 437.28 Mn | 1.86 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 7.38 Mn |
| Mar 31, 2026 | 6.33 Mn |
| Dec 31, 2025 | 6.62 Mn |
| Sep 30, 2025 | 8.80 Mn |
| Jun 30, 2025 | 10.79 Mn |
| Mar 31, 2025 | 4.76 Mn |
| Dec 31, 2024 | 5.51 Mn |
| Dec 31, 2023 | 636,956.43 |